"10.1371_journal.pone.0149768","plos one","2016-03-09T00:00:00Z","Marcel Hoppentocht; Onno W Akkerman; Paul Hagedoorn; Jan-Willem C Alffenaar; Tjip S van der Werf; Huib A M Kerstjens; Henderik W Frijlink; Anne H de Boer","Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, the Netherlands; Department of Pulmonary Diseases and Tuberculosis, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands","Conceived and designed the experiments: MH OWA JWCA TSW HAMK HWF AHB. Performed the experiments: MH OWA PH. Analyzed the data: MH OWA PH JWCA TSW HAMK HWF AHB. Contributed reagents/materials/analysis tools: MH OWA JWCA PH AHB. Wrote the paper: MH OWA PH JWCA TSW HAMK HWF AHB.","The employer of M. Hoppentocht, Dr. A.H. de Boer, Prof. Dr. H.W. Frijlink and P. Hagedoorn receives royalty payments over the sales of the NovolizerÂ®, GenuairÂ®/PressairÂ® and Twincerâ¢ dry powder inhalers. Prof. Dr. H.A.M. Kerstjens receives consultancy fees for his institution from: Novartis, Pfizer, Boehringer Ingelheim, Almirall, GlaxoSmithKline, Takeda, Chiesi, Protaffin, Nycomed and AstraZeneca. The other authors have no conflicts of interest to declare. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2016","03","Marcel Hoppentocht","MH",8,TRUE,7,3,8,8,TRUE,TRUE,FALSE,0,NA,FALSE
